XML 108 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
Property and Equipment
6 Months Ended
Jun. 30, 2013
Property, Plant and Equipment Assets Held-for-sale Disclosure [Abstract]  
Property and Equipment
Property and Equipment

 
(in thousands)
 
June 30,
2013
 
December 31,
2012
Land, buildings and improvements
$
4,209

 
$
4,209

Furniture, fixtures, and equipment
4,711

 
4,662

Leasehold improvements
85

 
85

 
 
 
 
Total property and equipment
9,005

 
8,956

Less: accumulated depreciation and amortization
(4,014
)
 
(3,664
)
 
 
 
 
Property and equipment, net
$
4,991

 
$
5,292


 
Property and equipment are recorded at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, ranging from five to thirty-nine years.

Construction in progress consists of funds used for the construction and installation of property and equipment within the Company's New Brunswick, NJ facility. As of June 30, 2013, construction in progress was $7,065,000 as compared to $6,580,000 as of December 31, 2012. The Company capitalized $90,000 as of June 30, 2013 as interest charges, as compared to $85,000 as of December 31, 2012, related to the construction in progress.

The Company owns and operates a 43,000 sq. ft. FDA approved facility in New Brunswick, NJ that produces Alferon® and Ampligen®. In December 2011, our Board of Directors (the “Board”) reevaluated the facility enhancement project to focus on upgrading the facility to provide for a high volume, more cost effective manufacturing process for Alferon N Injection®, Alferon® LDO and Ampligen®. The facility enhancement project is in its final stage with construction complete. The validation phase of the Alferon® manufacturing project is currently underway as we prepare to undertake the Installation Qualification Process phase of the enhancement project. Approximately $7,709,000 has been spent to date through June 30, 2013, as compared to $7,051,000 spent on the project through December 31, 2012, of which $7,051,000 has been financed through a Margin Account with an effective interest rate of approximately 2.50% (see "Note 9: Margin Account Loan").